Tomas L Lindahl
Overview
Explore the profile of Tomas L Lindahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arbring K, Lund M, Onelov L, Lindahl T
Scand J Clin Lab Invest
. 2025 Jan;
85(1):34-40.
PMID: 39854217
Background: Direct oral anticoagulants (DOACs) can interfere with coagulation analyses, causing erroneous results such as false-positive lupus anticoagulant and false-normal antithrombin, threatening patient safety when overlooked. A test using a...
2.
Ekholm M, Jekell A, Lundwall K, Alfredsson J, Lindahl T, Wallen H, et al.
Platelets
. 2024 Dec;
35(1):2437768.
PMID: 39681828
Drugs blocking the renin-angiotensin-aldosterone system may offer benefit on endothelial function, inflammation, and hemostasis in addition to the effects of reducing blood pressure. We have shown antithrombin effects by treatment...
3.
Heenkenda M, Traff E, Lindahl T, Venetsanos D, Alfredsson J
Platelets
. 2024 Dec;
35(1):2434225.
PMID: 39641456
ST-segment elevation myocardial infarction (STEMI) is usually caused by a ruptured atherosclerotic plaque, with subsequent thrombus formation. Platelet inhibition and primary percutaneous coronary intervention (PCI) are essential treatments. Morphine, used...
4.
Lindahl T, Kumar A, Hallstrom T, Al-Hashimi A, du Rietz A, Arlaman E, et al.
Thromb Haemost
. 2024 Nov;
PMID: 39586831
Background: Thrombin is a multifunctional regulatory enzyme of the haemostasis and has both pro- and anticoagulant roles. It has, therefore, been a main target for drug discovery over many decades....
5.
Karlsson A, Lindahl G, Holm A, Bergmark K, Dahm Kahler P, Fekete B, et al.
Acta Oncol
. 2024 Jul;
63:581-585.
PMID: 39037076
Background: Tinzaparin, a low-molecular weight heparin (LMWH), has shown anti-neoplastic properties in animal models and in in vitro studies of human cancer cell lines. The reduction of CA-125 levels during...
6.
Geijerstam P, Radholm K, Jonasson L, Lindahl T, Engvall J, Nystrom F, et al.
J Hypertens
. 2024 May;
42(7):1226-1234.
PMID: 38690927
Background: Soluble P-selectin (sP-selectin) and high-sensitivity C-reactive protein (hsCRP) have previously been associated with hypertension, but the relation with out-of-office blood pressure (BP) and coronary artery calcification score is unknown....
7.
Tunstromer K, Faxalv L, Larsson P, Lindahl T, Boknas N
Platelets
. 2023 Jan;
34(1):2157805.
PMID: 36631918
Pharmacological inhibition of the platelet ADP-receptor P2Y is a cornerstone in the prevention of atherothrombotic events in adult patients with acute coronary syndrome (ACS). Thienopyridines such as clopidogrel and prasugrel...
8.
Bian L, Baghaei F, Antovic J, Fagerberg Blixter I, Hillarp A, Strandberg K, et al.
Lakartidningen
. 2022 Jun;
119.
PMID: 35713306
Activated partial thromboplastin time (APTT) is widely practiced in preoperative screening. The value of using this test to predict the risk of perioperative bleeding is not well documented in Sweden....
9.
Boknas N, Laine C, Hillarp A, Macwan A, Gustafsson K, Lindahl T, et al.
Thromb Res
. 2022 Mar;
213:97-104.
PMID: 35316719
In this single-center cohort study, we applied a panel of laboratory markers to characterize hemostatic function in 217 consecutive patients that underwent testing for COVID-19 as they were admitted to...
10.
Lund M, Macwan A, Tunstromer K, Lindahl T, Boknas N
Front Cardiovasc Med
. 2021 Oct;
8:717835.
PMID: 34660719
Heparin and bivalirudin are widely used as anticoagulants in the setting of acute thrombosis. In this study, we investigated how these drugs affect the ability of thrombin to generate a...